NRAS
NRAS is a protein-coding gene encoding N-Ras, a member of the RAS family of small GTPase signaling proteins.
NRAS is a protein-coding gene encoding N-Ras, a member of the RAS family of small GTPase signaling proteins. N-Ras cycles between inactive GDP-bound and active GTP-bound states and participates in signal-transduction networks that include the RAF–MEK–ERK pathway. Dysregulated NRAS signaling—particularly through activating mutations—has been investigated in melanoma, hematologic malignancies, lung carcinoma, colorectal cancer, and other tumors.
NRAS is studied both as a disease-associated molecular alteration and as a therapeutic target. Its close relationship to KRAS and HRAS creates opportunities for shared pathway inhibition but also presents selectivity challenges. Current research includes direct RAS inhibition, downstream MEK targeting, combination chemotherapy, immune and microenvironmental interventions, and the use of NRAS status or expression as a biomarker for treatment response, resistance, or prognosis.
- Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. PMID 42714248
Where the papers sit
9 papers study nras directly. Those 9 do not group into themes. The set ranges from ctDNA and MRD allocation to NRAS/KRAS-targeted therapy, melanoma and leukemia models, and resistance profiling in colorectal cancer. It shares a focus on molecularly characterized cancer, but no single biological question or development direction. They are no more alike than papers drawn from anywhere in the corpus. 1 new direction follows.
NRAS is shown to remodel the bone-marrow niche in CMML
The CD69-blockade study in a mouse model of Nras G12D-driven chronic myelomonocytic leukemia treats NRAS not only as a leukemic-cell driver but as a determinant of the bone-marrow microenvironment. It found that CD69 blockade restores the bone-marrow niche and delays leukemogenesis, extending NRAS biology from tumor-cell signaling and biomarker status to regulation of the tissue environment that supports disease progression 42330053Jun.
Recent Findings on NRAS
Molecularly Defined Cancer Studies: NRAS serves as a molecular marker for detection, prognosis, treatment allocation, and resistance across several cancers. Pre-operative plasma ctDNA was undetectable in 12 high-risk primary melanomas with targetable BRAF or NRAS drivers, while N-RAS transcript level is being evaluated prognostically in node-negative muscle-invasive bladder cancer 42714248Sep42055839Apr. Trametinib produced clinical benefit in 37.5% of heavily pretreated NRAS-mutant cancers, but only one patient achieved a partial response 42361675Jun. A separate NRAS-mutant conjunctival melanoma case showed ex vivo sensitivity and sustained clinical benefit with MEK inhibition, indicating heterogeneous therapeutic responses 42537395Jul. Colorectal liver metastases contained NRAS alterations among broader anti-EGFR resistance profiles, although these subclonal mutations did not reduce secondary resectability; meanwhile, AM-2383 inhibited KRAS while sparing NRAS 42406708Jul42446418Jul. Preclinical models extend NRAS-directed strategies toward CD69 blockade in Nras G12D-driven CMML, mitochondria-directed nano-chitosan in NRAS-mutant lung carcinoma, and genetics-plus-MRD allocation in Philadelphia chromosome-negative acute lymphoblastic leukemia 42330053Jun42230031Jun42081455May.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-09-02. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.